Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

A new look at dry eye disease and its treatment.

Nelson JD, Helms H, Fiscella R, Southwell Y, Hirsch JD.

Adv Ther. 2000 Mar-Apr;17(2):84-93. Review.

PMID:
11010059
2.

Considerations in the pharmacoeconomics of dry eye.

Hirsch JD.

Manag Care. 2003 Dec;12(12 Suppl):33-8.

3.

The economic burden of dry eye: a conceptual framework and preliminary assessment.

Reddy P, Grad O, Rajagopalan K.

Cornea. 2004 Nov;23(8):751-61.

PMID:
15502474
4.

Prevalence, burden, and pharmacoeconomics of dry eye disease.

Pflugfelder SC.

Am J Manag Care. 2008 Apr;14(3 Suppl):S102-6. Review.

5.

Topical 0.05% cyclosporin in the treatment of dry eye.

Perry HD, Donnenfeld ED.

Expert Opin Pharmacother. 2004 Oct;5(10):2099-107. Review.

PMID:
15461545
6.

Prevalence of treated dry eye disease in a managed care population.

Yazdani C, McLaughlin T, Smeeding JE, Walt J.

Clin Ther. 2001 Oct;23(10):1672-82.

PMID:
11726003
7.

Dry eye diagnosis and management in 2004.

Perry HD, Donnenfeld ED.

Curr Opin Ophthalmol. 2004 Aug;15(4):299-304. Review.

PMID:
15232468
8.

Clinical and economic implications of topical cyclosporin A for the treatment of dry eye.

Cross WD, Lay LF Jr, Walt JG, Kozma CM.

Manag Care Interface. 2002 Sep;15(9):44-9.

PMID:
12244650
9.

Patient-reported symptoms in dry dye disease.

Nichols KK.

Ocul Surf. 2006 Jul;4(3):137-45. Review.

PMID:
16900269
10.

The treatment of dry eye.

Calonge M.

Surv Ophthalmol. 2001 Mar;45 Suppl 2:S227-39. Review.

PMID:
11587147
11.
12.

The economic burden of dry eye disease in the United States: a decision tree analysis.

Yu J, Asche CV, Fairchild CJ.

Cornea. 2011 Apr;30(4):379-87. doi: 10.1097/ICO.0b013e3181f7f363.

PMID:
21045640
13.

Prevalence of dry eye disease among Japanese visual display terminal users.

Uchino M, Schaumberg DA, Dogru M, Uchino Y, Fukagawa K, Shimmura S, Satoh T, Takebayashi T, Tsubota K.

Ophthalmology. 2008 Nov;115(11):1982-8. doi: 10.1016/j.ophtha.2008.06.022. Epub 2008 Aug 16.

PMID:
18708259
14.

Prevalence of ocular surface disease in glaucoma patients.

Leung EW, Medeiros FA, Weinreb RN.

J Glaucoma. 2008 Aug;17(5):350-5. doi: 10.1097/IJG.0b013e31815c5f4f.

PMID:
18703943
15.

Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment.

Wilson SE, Perry HD.

Ophthalmology. 2007 Jan;114(1):76-9. Epub 2006 Oct 27.

PMID:
17070588
16.

Utilization characteristics of topical cycolsporine and punctal plugs in a managed care database.

Fiscella RG, Lee JT, Walt JG, Killian TD.

Am J Manag Care. 2008 Apr;14(3 Suppl):S107-12.

17.

United States cost-effectiveness study of two dry eye ophthalmic lubricants.

Wlodarczyk J, Fairchild C.

Ophthalmic Epidemiol. 2009 Jan-Feb;16(1):22-30. doi: 10.1080/09286580802521309.

PMID:
19191178
18.
19.

Utility assessment among patients with dry eye disease.

Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W.

Ophthalmology. 2003 Jul;110(7):1412-9.

PMID:
12867401
20.

Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.

Cordero-Coma M, Anzaar F, Sobrin L, Foster CS.

Ocul Immunol Inflamm. 2007 Mar-Apr;15(2):99-104.

PMID:
17558834

Supplemental Content

Support Center